Drug Profile
MDL 210053
Latest Information Update: 03 Jul 2002
Price :
$50
*
At a glance
- Originator Aventis
- Class Antirheumatics
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 22 Feb 1995 Preclinical development for Rheumatic disorders in USA (Unknown route)